Navigation Links
Mindray Medical Provides Mid-Year Update on Product Development
Date:7/19/2010

SHENZHEN, China, July 19 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced updates on new product launches for the first half of 2010.

In the first half of the year, the company successfully released a total of four products across its three product lines. These include: a lower-end surgical bed, an additional advanced biochemistry analyzer; a feature-enhanced hand-carried color ultrasound system; and a new digital radiography system model. Full product descriptions are provided below.

"We are excited about the progress we have made with the addition of these four new products," commented Mr. Li Xiting, Mindray's president and co-chief executive officer. "Mindray continues to be aggressive in bringing its high-quality, competitively-priced products to market. A strong R&D initiative is an integral part of Mindray's strategy to maintain competitive advantage and generate additional revenue from new market opportunities. We are pleased with the current development of our product lines and are well-positioned to meet our goal of launching an additional seven to nine products in 2010."

    Products

    Patient Monitoring and Life Support
    -- HyBase 1000 - is a lower-end surgical bed that provides maximum comfort
       and great convenience to end-users, can suit various surgical
       disciplines, and offers a full-safety guarantee.

    In-Vitro Diagnostic Products
    -- BS-800 - is the newest high-level instrument from Mindray. This model
       not only provides superior performance and reliability, but is also
       innovative in structure, function, and application.

    Medical Imaging System
    -- M-7 - is an upgraded hand-carried color ultrasound system which
       received both the CE mark and FDA approval. A winner of the prestigious
       2010 Reddot design award, M7 is a productivity power station designed
       to meet current and future customer needs. With its sharp and clear
       image quality, M-7 can be used for diagnoses across a broad spectrum,
       including the abdominal, vascular and cardiac specialties. M7 enables
       clinicians to achieve an enhanced level of diagnostic confidence and
       efficiency.

    -- DigiEye 760 - is the second model in Mindray's Digital Radiographic
       System and mainly consists of an FPD (flat-panel detector), X-ray
       generator, X-ray tube, mobile patient table, ceiling suspension and
       integrated workstation with the most advanced and innovative software
       technologies.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global operational headquarters in Shenzhen, China, and multiple sales offices in major domestic and international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com .

    For investor and media inquiries please contact:

    In the U.S.:

     John Capodanno
     FD
     Tel:   +1-212-850-5705
     Email: john.capodanno@fd.com

     Bryan Armstrong
     FD
     Tel:   +1-312-553-6707
     Email: bryan.armstrong@fd.com

    In China:

     May Li
     Mindray Investor Relations
     Tel:   +86-755-2658-2518
     Email: ir@mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray Medical to Present at J.P. Morgan China Conference 2010
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... and Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Electrodes Market is poised to grow at a CAGR of around ... the market is witnessing include advancements in extracellular microelectrode arrays and ...
Breaking Medicine Technology:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... planning services from offices headquartered in Jefferson County, is announcing the launch of ... in Birmingham. , The number of homeless women and children in Birmingham has ...
Breaking Medicine News(10 mins):